Embodiments of the present invention are directed to methods, apparatus and articles of manufacture that feature omega-3 fatty acids co-processed with flavonoid and lipophilic antioxidants for improved stability.

The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof

The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof

The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof

Products are described for treating epithelial tissues of the human or animal body including liquid compositions containing whole blood, or parts of blood including blood plasma, blood serum, blood platelets and growth factors derivable from blood. Other compositions disclosed include solid reservoirs of collagen or amniotic membrane into which whole blood or parts of blood have been absorbed. Methods of treatment using these compositions are described, in particular for treatment of ophthalmic disorders such as dry-eye and oral disorders such as dry mouth. A range of devices (1, 11, 31, 41, 51, 61, 71, 81, 91, 101) are described for sampling, mixing, storing and/or applying blood and compositions containing blood and parts of blood.

Products are described for treating epithelial tissues of the human or animal body including liquid compositions containing whole blood, or parts of blood including blood plasma, blood serum, blood platelets and growth factors derivable from blood. Other compositions disclosed include solid reservoirs of collagen or amniotic membrane into which whole blood or parts of blood have been absorbed. Methods of treatment using these compositions are described, in particular for treatment of ophthalmic disorders such as dry-eye and oral disorders such as dry mouth. A range of devices (1, 11, 31, 41, 51, 61, 71, 81, 91, 101) are described for sampling, mixing, storing and/or applying blood and compositions containing blood and parts of blood.

The present disclosure describes a novel anhydrous topical pharmaceutical composition comprised of marine oil, such as fish oil or algae oil; vegetable oil having a an omega3 fat content greater than 9 wt %, such as hempseed oil, canola oil, flax seed oil, or cannabidiol; monolaurin, cetyl esters or wax; and medium chain triglycerides (“MCT”), and optionally fish collagen. The composition is useful for treating wounds, burns and skin conditions.

The present disclosure describes a novel anhydrous topical pharmaceutical composition comprised of marine oil, such as fish oil or algae oil; vegetable oil having a an omega3 fat content greater than 9 wt %, such as hempseed oil, canola oil, flax seed oil, or cannabidiol; monolaurin, cetyl esters or wax; and medium chain triglycerides (“MCT”), and optionally fish collagen. The composition is useful for treating wounds, burns and skin conditions.

A composition for decreasing proliferation of cancer cells undergoing hyperthermia therapy is described. Such compositions can include a combination of selenium and fish oil. The respective quantities of selenium and fish oil are provided in amounts effective to synergistically increase the sensitivity of the cancer cells to temperatures in excess of 37° C.

A composition for decreasing proliferation of cancer cells undergoing hyperthermia therapy is described. Such compositions can include a combination of selenium and fish oil. The respective quantities of selenium and fish oil are provided in amounts effective to synergistically increase the sensitivity of the cancer cells to temperatures in excess of 37° C.